Imaging Astrogliosis in Patients with Epilepsy with [18F]-FDED PET

Imaging Astrogliosis with [18F]fluorodeprenyl-D2 ([18F]-FDED) PET in Patients with Drug-Resistant Epilepsy Planning Resective Epilepsy Surgery.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12625000170426

Enrollment

Registered

2025-02-13

Start date

2025-02-24

Completion date

2029-12-31

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Temporal lobe epilepsy is the most common form of focal epilepsy, and is commonly resistant to treatment with anti-seizure medications (ASMs). Successful epilepsy surgery is dependent on accurate delineation (and resection) of the epileptogenic zone (EZ). Astrocytes are a type of immune cell within the brain which are activated in response to acute injury or insult. Studies have demonstrated that activated astrocytes are present in surgically resected tissue of people with epilepsy, with other studies suggesting dysfunctional astrocytes contribute to seizure generation and propagation in drug resistant epilepsy. 18F-FDED, binds to the mono-amine oxidase B enzyme which is expressed on the surface of activated astrocytes, thus the present study will evaluate 18F-FDED PET as a technique for localising the EZ in patients with focal epilepsy.

Interventions

PET imaging will be conducted at the Alfred Hospital Nuclear Medicine Department. Patients with temporal lobe epilepsy will undergo a single 60-minute dynamic PET scan with 18F-FDED (intravenous injection - 200MBq +/- 10%), prior to resective epilepsy surgery though not at any specific time point prior. Patients will also undergo MRI and EEG prior to surgery.

Study design

Allocation

Non-randomised trial

Primary purpose

Diagnosis

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

Epilepsy group: 1. Age 18-60 years 2. Clinical diagnosis of drug-resistant epilepsy (except drug responsive and healthy control groups) 3. Currently undergoing work up for resective epilepsy surgery 4. Previously completed MRI, FDG PET and video EEG for localisation of EZ and comparison with FDED-PET 5. Able to self-consent Control group: 1. Age 18-60 years 2. Able to self-consent

Exclusion criteria

All participants (Epilepsy and control): 1. Pregnant or breastfeeding 2. Unstable medical condition that could impact participant safety or completion of study procedures 3. Current or recent (<3 months) cannabinoid use (either recreational or medicinal)

Outcome results